OPAR: A Randomized Trial of Partial Breast Irradiation in Five Fractions Once Daily for Early Breast Cancer
Abstract
PURPOSE Previous studies suggest that external-beam partial breast irradiation (PBI) delivered twice a day can lead to increased adverse cosmesis (AC). The objective of our trial was to determine whether two regimens for PBI given once daily over 1 week resulted in acceptable AC to inform a phase III trial. METHODS Patients age ≥50 years with invasive breast cancer or ductal carcinoma in situ, ≤3 cm in size treated by lumpectomy with negative axillary nodes were randomly assigned to external-beam PBI of 30 Gy or 27.5 Gy, each given in five fractions once daily. The primary outcome was AC (fair or poor) by photographic assessment at 2 years. Secondary outcomes included AC assessed by nurse at 2 years, by patient self-assessment at 3 years, and late toxicity. On the basis of a 17% risk of AC with whole-breast irradiation, the upper bound of a two-sided 90% CI, 23% was set as the tolerance margin (OPAR, ClinicalTrials.gov identifier: NCT02637024 ). RESULTS In total, 142 patients were randomly assigned to 30 Gy and 139 to 27.5 Gy. The median follow-up was 5 years. The mean age was 65 years, and the mean tumor size was 1.2 cm. Both schedules met acceptability criteria by photographic assessment (AC, 12.1% [90% CI, 8.2 to 17.6] for 30 Gy and 15.2% [90% CI, 10.8 to 21.1] for 27.5 Gy) and by nurse assessment. AC by patient self-assessment exceeded the 90% CI for the 30 Gy regimen. At 5 years, 16 (11.3%, 90% CI, 7.6 to 16.4) patients treated with 30 Gy and eight (5.8%, 90% CI, 3.3 to 9.9) patients treated with 27.5 Gy were observed to have grade 2 or more late toxicity. CONCLUSION According to the study design, 30 Gy and 27.5 Gy resulted in acceptable cosmetic outcomes. In light of recent studies, a lower dose was chosen for the phase III trial.
Article Details
Journal Info
Journal of Clinical Oncology
Lippincott Williams & Wilkins
Authors (17)
Do-Hoon Kim
Division of Radiation Oncology, Department of Oncology, McMaster University and Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, ON, Canada
Valérie Théberge
CHU de Québec-Université Laval, Quebec City, QC, Canada
Sameer Parpia
Iwa Kong
BC Cancer Vancouver, Vancouver, BC, Canada
Sawyna Provencher
Department of Radiation Oncology, Centre Hospitalier Universitaire de Sherbrooke (CHUS), Sherbrooke, QC, Canada
Michael Yassa
Department of Radiation Oncology, Maisonneuve-Rosemont Hospital, Montreal, QC, Canada
Francisco Perera
Department of Radiation Oncology, Western University and London Regional Cancer Program, London, ON, Canada
Sophie Lavertu
Department of Radiation Oncology, Universite de Laval and Hôtel-Dieu de Lévis, Lévis, QC, Canada
Pierre Rousseau
Department of Radiation Oncology, Universite de Montreal, Montreal, QC, Canada
Justin Lee
Department for Biochemistry of Plant Interactions, Leibniz Institute of Plant Biochemistry
Irene Karam
Sunnybrook Health Sciencies, Toronto, ON, Canada
Kenneth Schneider
Department of Radiation Oncology, Windsor Regional Cancer Centre, Windsor, ON, Canada
Mark N. Levine
Department of Oncology, McMaster University, Hamilton, ON, Canada
Timothy J. Whelan
McMaster University, Hamilton, ON, Canada
Christiaan Stevens
Ramana Rachakonda
Tarek Hijal
McGill University Health Centre, Montreal, QC, Canada